"We are excited because this further validates the important role that bioinformatics can play in the development of diagnostic tools and ultimately vaccines," said Alessandro Sette, Ph.D., an internationally known vaccine expert and head of LIAI's Emerging Infectious Disease and Biodefense Center. "We've shown that it can successfully reveal - with a very high degree of accuracy -- the vast majority of the epitopes (targets) that would trigger an effective immune response against a complex pathogen."
Bioinformatics holds significant interest in the scientific community because of its potential to move scientific research forward more quickly and at less expense than traditional laboratory testing.
The findings were published this week in a paper, "A consensus epitope prediction approach identifies the breadth of murine TCD8+-cell responses to vaccinia virus," in the online version of the journal Nature Biotechnology. LIAI scientist Magdalini Moutaftsi was the lead author on the paper.
While bioinformatics - which uses computer databases, algorithms and statistical techniques to analyze biological information -- is already in use as a predictor of immune response, the LIAI research team's findings were significant because they demonstrated an extremely high rate of prediction accuracy (95 percent) in a very complex pathogen - the vaccinia virus. The vaccinia virus is a non-dangerous virus used in the smallpox vaccine because it is related to the variola virus, which is the agent of smallpox. The scientific team was able to prove the accuracy of their computer results through animal testing.
"Before, we knew that the prediction methods we were using were working, but this study proves that they work very well with a high degree of accuracy," Sette said.
The researchers focused their testing on the Major Histocompatibility Complex (MHC), which binds to certain epitopes and is key to triggering the immune system to attack a virus-infected cell. Epitopes are pieces of a virus that the body's immune system focuses on when it begins an immune response. By understanding which epitopes will bind to the MHC molecule and cause an immune attack, scientists can use those epitopes to develop a vaccine to ward off illness - in this case to smallpox.
The scientists were able to find 95 percent of the MHC binding epitopes through the computer modeling. "This is the first time that bioinformatics prediction for epitope MHC binding can account for almost all of the (targeted) epitopes that are existing in very complex pathogens like vaccinia," said LIAI researcher Magdalini Moutaftsi. The LIAI scientists theorize that the bioinformatics prediction approach for epitope MHC binding will be applicable to other viruses.
"The beauty of the virus used for this study is that it's one of the most complex, large viruses that exist," said Moutaftsi. "If we can predict almost all (targeted) epitopes from such a large virus, then we should be able to do that very easily for less complex viruses like influenza, herpes or even HIV, and eventually apply this methodology to larger microbes such as tuberculosis."
The big advantage of using bioinformatics to predict immune system targets, explained Sette, is that it overcomes the need to manufacture and test large numbers of peptides in the laboratory to find which ones will initiate an immune response. Peptides are amino acid pieces that potentially can be recognized by the immune system. "There are literally thousands of peptides," explained Sette. "You might have to create and test hundreds or even thousands of them to find the right ones," he said. "With bioinformatics, the computer does the screening based on very complex mathematical algorithms. And it can do it in much less time and at much less expense than doing the testing in the lab."
The LIAI scientific team verified the accuracy of their computer findings by comparing the results against laboratory testing of the peptides and whole infectious virus in mice. "We studied the total response directed against infected cells," Sette said. "We compared it to the response against the 50 epitopes that had been predicted by the computer. We were pleased to see that our prediction could account for 95% of the total response directed against the virus."
Founded in 1988, the La Jolla Institute for Allergy and Immunology is a nonprofit medical research center dedicated to increasing knowledge and improving human health through studies of the immune system. Scientists at the institute carry out research searching for cures for cancer, allergy and asthma, infectious diseases, and autoimmune diseases such as diabetes, inflammatory bowel disease and arthritis. LIAI's research staff includes more than 100 Ph.Ds.